Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Huge Global Blood Cancer Market
View:
Post by Eoganacht on Apr 09, 2024 9:16am

Huge Global Blood Cancer Market

Today's Stockhouse article lays it all out:

This company’s Photo Dynamic Therapy is transforming cancer treatment 


"Broadly speaking, the global blood cancer drug market is expected to reach a valuation of $108 billion by 2031, with the increasing prevalence of blood cancer driving that growth."

https://stockhouse.com/news/newswire/2024/04/09/this-company-s-photo-dynamic-therapy-transforming-cancer-treatment
Comment by CAinPlap on Apr 09, 2024 10:25am
Nice article but how many "market darlings" have a market cap of only $35 Million? 
Comment by skys1 on Apr 09, 2024 10:28am
Eogan - terrific article!!!
Comment by Infinity on Apr 09, 2024 10:33am
Brilliant article.  I am getting tired of these.  Why are we still struggling at $0.16?  Does it mean no one else values TLT and their Patents or their cures that are in pipe line
Comment by Alamir1111 on Apr 09, 2024 10:59am
Sept 2022 The company plans to use the proceeds of the financing for a Good Laboratory Practice toxicology study for intravenous installation of Rutherrin, Good Laboratory Practice (“GLP”) Toxicology Study for Intravenous installation of Rutherrin intended for the treatment of Non Small Lung Cancer (“NSCLC”) and Glio Blastoma Multiforme (“GBM”) Good Laboratory Practice (“GLP ...more  
Comment by Dumbeldorfwhite on Apr 09, 2024 10:31pm
No money, constant delays, overshooting expectations. Just look at alamirs post, they be been doing toxicology studies for "2 years" now on GBM and NSCLC. It's always well if we had more money, you raised 22 million and got what, halfway through the trial. O and the enrollment is so slow I would expect it to be 2027 or 2028 for completion/commercialization, by then it is reasonable ...more  
Comment by chry200030 on Apr 10, 2024 12:51am
Better sell then. I wonder whom the many companies are you are talking about.. I expect to see some nice share price accumulation by end of June 2024. It will be the start. 
Comment by Dumbeldorfwhite on Apr 10, 2024 6:29am
You can start with Creto who has superior results compared ours strictly efficacy speaking
Comment by rhodiumd on Apr 10, 2024 10:58am
New patient enrollment will pick up after the advisor meetings. I think doctors are so swamped that they don't have time to look at the new research and numbers and most of them stay in the loop during conferences and such meetings. This is why companies are always so eager to present new data at conferences and meetups. 
Comment by Dumbeldorfwhite on Apr 10, 2024 12:16pm
Man the excuses you guys come up with are hilarious, doctors involved in research are very up to date with results.  My guess is the complexity of the procedure is what is holding some back.
Comment by CAinPlap on Apr 10, 2024 1:15pm
Complexity of the procedure??? Seems pretty straight forward to me. My jaded opinion is we don't have the $ to grease the PI's to promote our trial over the Big Pharma trials. I would love to be a fly on the wall when Doc's are discussing trial options with patients. This should be the way it goes - Hey patient you can go with the Big pharma option with its 20 or more treatments and ...more  
Comment by riverrrow on Apr 10, 2024 1:57pm
Even SNC Lavalin wasn't legally able to apply grease.  It's the Canadian way.  I don't know how TLT is going to get out of this bind.  GLTA.
Comment by Dumbeldorfwhite on Apr 10, 2024 3:21pm
LMAO ya ll know they didn't even treat the first 12 correctly right? Clearly it is not a straightforward procedure 
Comment by riverrrow on Apr 10, 2024 10:04pm
The fact is that the CR rate for the 12 underdosed patients is not that much lower than for the correctly dosed.  And then of course there are the two out of three  patients in phase 1 that went, what, 2 years CR or something.
Comment by charlierock on Apr 10, 2024 2:49pm
No complexity. Nothing to see here. It's more like simplicity relativity speaking. My main concerns are; is BTD coming our way soon without anymore hurdles? How widely will our ACT be adopted? How bout a nice big joint venture or ventures. I think this is the year when we'll get some answers and maybe some surprises.
Comment by Eoganacht on Apr 10, 2024 3:47pm
If our trial results remain good and durability of response remains high, it's difficult to understand how urologists could defend not using Ruvidar PDT once it's approved. Conservatively, one third of patients treated will be completely cured of NMIBC after only one or two treatments without any serious adverse effects attributable to the treatment. And maybe more than one third. It ...more  
Comment by Legit62 on Apr 10, 2024 4:33pm
So true Eoganacht, just got to get FDA approval and off and running
Comment by Dumbeldorfwhite on Apr 10, 2024 5:14pm
What seems to you is not panning out in the enrollment, thus clearly urologists do not like or are of the application of the treatment. Scream til your face is blue, facts are facts, they enrolled what 2 people this year? And they said they want everyone enrolled by end of year? Hahahahahahahahha April fools
Comment by Legit62 on Apr 10, 2024 5:58pm
Dumber than Dumb time for you to invest in Bitcoin and rid yourself of TLT if you feel we are doomed, JMO, we are here because we believe in technology good or bad, you fd up if you lost money here, move on and save yourself the pity please
Comment by Dumbeldorfwhite on Apr 10, 2024 6:17pm
Naaaa I like giving the good ole boys club a dose of reality. Hey don't blame me you like losing money year after year, I actually want to make money
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250